Welcome, Guest. Please login or register.
April 07, 2020, 10:49:27 am

Login with username, password and session length


Members
  • Total Members: 6203
  • Latest: Jgrace
Stats
  • Total Posts: 54824
  • Total Topics: 4729
  • Online Today: 71
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 1
Guests: 44
Total: 45

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Opdivo Shows Mixed Results for Liver Cancer  (Read 505 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 706
    • Hep Mag
Opdivo Shows Mixed Results for Liver Cancer
« on: October 21, 2019, 11:07:35 am »
The checkpoint inhibitor Opdivo (nivolumab) did not reach the statistical threshold for improved overall survival compared with standard targeted therapy for people with advanced liver cancer, but it did appear to be better tolerated, according to research presented at the European Society for Medical Oncology Congress (ESMO 2019) this week in Barcelona.

The median overall survival was 16.4 months for patients taking Opdivo versus 14.7 months for those using Nexavar (sorafenib) in a late-stage study. Although this difference did not meet the study’s high bar for statistical significance, meaning it could have been driven by chance, people taking Opdivo had fewer severe side effects and were less likely to stop treatment for this reason.

Read more...
https://www.hepmag.com/article/opdivo-shows-mixed-results-liver-cancer

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.